Wheezing
1
Pipeline Programs
5
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Physical SciencesMA - Andover
1 programLung function monitoring equipment at home - 2 weeksN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Verona PharmaMontelukast
Colorado TherapeuticsSoy isoflavone
Physical SciencesLung function monitoring equipment at home - 2 weeks
Clinical Trials (3)
Total enrollment: 205 patients across 3 trials
Montelukast in Children With Wheezing
Start: Sep 2009Est. completion: Dec 201440 patients
Phase 4Unknown
Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study
Start: Sep 2024Est. completion: Dec 202865 patients
Phase 2Recruiting
Remote Monitoring in Preschool Wheeze
Start: Aug 2022Est. completion: Mar 2024100 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 205 patients
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.